- Home
- BBAI vs COLL Comparison
BBAI vs COLL Comparison
Compare BBAI & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBAI
- COLL
- Stock Information
- Founded
- BBAI 2020
- COLL 2002
- Country
- BBAI United States
- COLL United States
- Employees
- BBAI N/A
- COLL N/A
- Industry
- BBAI EDP Services
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- BBAI Technology
- COLL Health Care
- Exchange
- BBAI Nasdaq
- COLL Nasdaq
- Market Cap
- BBAI 1.0B
- COLL 910.2M
- IPO Year
- BBAI N/A
- COLL 2015
- Fundamental
- Price
- BBAI $3.03
- COLL $29.71
- Analyst Decision
- BBAI Strong Buy
- COLL Strong Buy
- Analyst Count
- BBAI 3
- COLL 5
- Target Price
- BBAI $5.17
- COLL $43.60
- AVG Volume (30 Days)
- BBAI 43.8M
- COLL 466.9K
- Earning Date
- BBAI 03-06-2025
- COLL 05-08-2025
- Dividend Yield
- BBAI N/A
- COLL N/A
- EPS Growth
- BBAI N/A
- COLL 43.56
- EPS
- BBAI N/A
- COLL 1.86
- Revenue
- BBAI $158,236,000.00
- COLL $631,449,000.00
- Revenue This Year
- BBAI $29.43
- COLL $19.43
- Revenue Next Year
- BBAI $24.51
- COLL $3.34
- P/E Ratio
- BBAI N/A
- COLL $16.00
- Revenue Growth
- BBAI 1.98
- COLL 11.41
- 52 Week Low
- BBAI $1.17
- COLL $27.28
- 52 Week High
- BBAI $10.36
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- BBAI 36.51
- COLL 48.90
- Support Level
- BBAI $2.85
- COLL $29.33
- Resistance Level
- BBAI $3.83
- COLL $30.84
- Average True Range (ATR)
- BBAI 0.27
- COLL 0.85
- MACD
- BBAI 0.03
- COLL 0.08
- Stochastic Oscillator
- BBAI 17.86
- COLL 50.11
About BBAI BigBear.ai Inc.
BigBear.ai Holdings Inc is a technology-led solutions organization, that provides both software and services to its customers. Its AI-powered decision intelligence solutions are leveraged in three markets; supply chains & logistics, autonomous systems, and cybersecurity. It operates in two segments; Cyber & Engineering segment and Analytics segment.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.